Your browser doesn't support javascript.
loading
Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment.
Pan, Ya-Ru; Liu, Si-Qi; He, Yi-Shan; Xue, Yuan; Wang, Jian; Huang, Rui; Wu, Chao; Lu, Jian-Chun; Liu, Long-Gen.
Afiliação
  • Pan YR; Changzhou Clinical Medical College, Nanjing Medical University, Changzhou, Jiangsu Province, China.
  • Liu SQ; Changzhou Clinical Medical College, Nanjing Medical University, Changzhou, Jiangsu Province, China.
  • He YS; Changzhou Clinical Medical College, Nanjing Medical University, Changzhou, Jiangsu Province, China.
  • Xue Y; Changzhou Clinical Medical College, Nanjing Medical University, Changzhou, Jiangsu Province, China.
  • Wang J; Institute of Hepatology, The Third People's Hospital of Changzhou, Changzhou, Jiangsu Province, China.
  • Huang R; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province, China.
  • Wu C; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province, China.
  • Lu JC; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province, China.
  • Liu LG; Changzhou Clinical Medical College, Nanjing Medical University, Changzhou, Jiangsu Province, China.
Ann Med ; 55(1): 760-765, 2023 12.
Article em En | MEDLINE | ID: mdl-36856541
BACKGROUND: Decrease in estimated glomerular filtration rate (eGFR) during Tenofovir disoproxil fumarate (TDF) treatment remains a concern, and few patients experience partial recovery of eGFR. This study aimed to investigate the risk factors for eGFR recovery in patients with and without hypertriglyceridemia. METHODS: A total of 203 patients with chronic HBV infection were prospectively recruited and followed up for three years. Data were collected at baseline, first, second, and third years during TDF treatment. RESULTS: Most patients achieved normal ALT (80.0% vs. 82.5%) and undetectable HBV DNA (95.0% vs. 95.6%) in both groups (p > 0.05). For patients with hypertriglyceridemia, eGFR and cholesterol did not change significantly during the 3-year follow-up, while triglyceride (TG) decreased significantly in the first year and persisted at a lower level in the subsequent two years. For patients without hypertriglyceridemia, eGFR declined significantly in the first year of treatment, then gradually recovered during the subsequent two years, and eGFR was negatively correlated with TG at the four time points. Fifteen (15/183, 8.2%) patients without hypertriglyceridemia experienced eGFR partial recovery in the third year. Univariate and multivariate analyses showed that baseline eGFR <90 mL/(min·1.73 m2) (p < 0.01; 95% CI: 0.019-0.284) and age (p < 0.01; 95% CI: 0.817-0.960) were independent risk factors for eGFR recovery. CONCLUSION: eGFR partially recovered in patients without hypertriglyceridemia during TDF treatment, and TG regulation might be a useful strategy to hinder renal function decline, although larger, confirmatory studies are necessary to validate our findings.Key messagesFor patients with normal triglyceride, eGFR declined significantly at the first year of TDF treatment, then gradually recovered during the subsequent two years, and eGFR was negatively correlated with TG. Baseline eGFR <90 mL/(min·1.73 m2) and age were independent risk factors for eGFR recovery.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipertrigliceridemia Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipertrigliceridemia Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article